84 related articles for article (PubMed ID: 20854434)
1. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins.
Martin M; Ott H; Merk HF; Sachs B
Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434
[TBL] [Abstract][Full Text] [Related]
2. [Anaphylactoid reactions associated with contaminated heparin from China].
Montpas N; Désormeaux A; Keire D; Adam A
Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
[TBL] [Abstract][Full Text] [Related]
3. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
Lindahl U
Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
[No Abstract] [Full Text] [Related]
4. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
5. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
Warkentin TE; Greinacher A
Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
[TBL] [Abstract][Full Text] [Related]
6. Contaminants in heparins continue to be unfolded.
Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
[No Abstract] [Full Text] [Related]
7. [Hypersensitivity reaction and Chinese heparin].
Désormeaux A; Montpas N; Adam A
Ann Pharm Fr; 2009 May; 67(3):169-72. PubMed ID: 19446665
[TBL] [Abstract][Full Text] [Related]
8. The tainted heparin story: an update.
Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
[TBL] [Abstract][Full Text] [Related]
9. Contaminated heparin.
Greinacher A; Warkentin TE
N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
[No Abstract] [Full Text] [Related]
10. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
11. [Contaminated heparins].
Monneret C
Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
[TBL] [Abstract][Full Text] [Related]
12. Contaminated heparin associated with adverse clinical events and activation of the contact system.
Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
[TBL] [Abstract][Full Text] [Related]
13. Contaminated heparin.
Kakkar AK; Bonnefoi M
N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
[No Abstract] [Full Text] [Related]
14. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins.
Lopez S; Torres MJ; Rodríguez-Pena R; Blanca-Lopez N; Fernandez TD; Antunez C; Canto G; de Luque V; Mayorga C
Br J Dermatol; 2009 Feb; 160(2):259-65. PubMed ID: 18945304
[TBL] [Abstract][Full Text] [Related]
15. Contaminated heparin preparations, severe adverse events and the contact system.
Ramacciotti E; Wahi R; Messmore HL
Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
[No Abstract] [Full Text] [Related]
16. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
[TBL] [Abstract][Full Text] [Related]
17. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
[TBL] [Abstract][Full Text] [Related]
18. Contaminated heparin-affected patient plasmas are associated with activated contact systems.
Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Beck AM; Shih FF; Lijuan Zhang
Clin Appl Thromb Hemost; 2010 Jun; 16(3):261-5. PubMed ID: 20547554
[No Abstract] [Full Text] [Related]
19. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.
Adam A; Montpas N; Keire D; Désormeaux A; Brown NJ; Marceau F; Westenberger B
Biomaterials; 2010 Aug; 31(22):5741-8. PubMed ID: 20427081
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
